GoldenGolden
Advanced Search
HelixNano

HelixNano

HelixNano is a Cambridge, Massachusetts-based biotechnology and artificial intelligence company founded in 2013 by Hannu Rajaniemi and Nikolai Eroshenko.

HelixNano is a developer of a biotechnological platform intended to help in gene delivery. The company's platform uses artificial intelligence to leverage synthetic biology to safely and reliably express trans-genes in humans for next-generation gene therapies, genome engineering and beyond, enabling healthcare industry to help cure genetic diseases.

HelixNano is a Y Combinator and venture backed biotech startup. Their mission is to solve gene delivery.

Personalized Cancer Vaccines

In 2019, HelixNano announced a Grant from Schmidt Futures to pursue personalized cancer vaccines. With the grant, and in collaboration with the Hacohen Lab at the Broad Institute and the Parker Institute for Cancer Immunotherapy to use synthetic biology and machine learning to reduce the uncertainty of neoantigen design. The team worked to develop a method to transform any neoantigen candidate into a precision neoantigen, thereby guaranteeing an immune response and boosting efficacy.

HelixNano's strategy for generating a cancer vaccine would focus on mRNA, having it deliver a message to kill cancer cells and attract immune cells to a tumor.

COVID-19

In March 2020, HelixNano suspended their work on cancer vaccines in favor of working to develop a vaccine for SARS-CoV-2. HelixNano intends to use their platform to accelerate efforts at finding a vaccine in the hopes of reducing the expected delivery time of a vaccine from 18 months to 6 months.

HelixNano's strategy for generating a vaccine for SARS-CoV-2 is centered on mRNA. The strategies similarities to their cancer vaccine allowed HelixNano to refocus their infrastructure rapidly. Their vaccine strategy includes developing a vaccine to work against possible mutations of SARS-CoV-2.

Timeline

May 2020
HelixNano raises a $50,000 convertible note from Todd tweedy.
April 2020
HelixNano raises a $300,000 convertible note from Hopper-Dean Investors.
April 2020
HelixNano raises a $27,000 convertible note from Odesangel AB.
March 2020
HelixNano raises a $350,000 convertible note from Marstar Alternative Investments.
March 2020
HelixNano raises a $110,000 convertible note from Starlight Ventures.
March 2020
HelixNano raises a $1,100,000 convertible note from Altman Family, LLC, Foobar Technologies, Incite Labs, Inc. and Vorago Holdings Oy.
November 2019
HelixNano raises a $50,000 convertible note from Ari Helgason and Ingvar Helgason.
November 2019
HelixNano raises a $450,000 convertible note from Jeff dean and Jussi laakkonen.
October 2019
HelixNano raises a $250,000 convertible note from Foobar Technologies.
February 7, 2019
HelixNano Announces Grant from Schmidt Futures to Pursue Personalized Cancer Vaccines.
Page 1 of 2

Funding rounds

People

Name
Role
LinkedIn

Carina Namih

Commercial Advisor

George M. Church

Scientific Advisor

Hannu Rajaniemi, PhD

Founder and CEO

Jose Trevejo, MD, PhD

Clinical and Translational Advisor

Nikolai Eroshenko, PhD

Founder and CSO

Further reading

Title
Author
Link
Type
Date

Group run by former Google CEO to hold meeting with VCs, philanthropists about ways to fight coronavirus

Brian Schwartz

Web

March 17, 2020

What it's like to invent a coronavirus vaccine in the middle of a pandemic

Cat Clifford

Web

April 24, 2020

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.